"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: COMBINATION_PRODUCT: Atezolizumab + RP1
Sponsor: Institut Curie
Collaborators: Replimune Inc.|Roche Pharma AG